Smart supramolecular assembly for pathology-responsive and long-acting drug delivery applications
Not stated
- Funding
- Self-Funded PhD Students Only
- Application deadline
- Year-round applications
About the project
About the Project This PhD will design and develop ionic liquid–enabled supramolecular formulations capable of in situ sol-to-gel transition triggered by pathological microenvironmental cues such as acidic pH, reactive oxygen species (ROS), and enzyme activity. The project will combine computational prediction with experimental optimisation to engineer self-assembling, pathology-responsive depots for localised and sustained therapeutic delivery. This work will deepen understanding of ionic-liquid–driven self-assembly, dynamic drug–excipient interactions, and adaptive viscoelasticity, paving the way for next-generation long-acting and pathology-adaptive drug delivery systems for cancer, inflammation, and rare diseases. Training that will be provided through the research project The PhD researcher will receive comprehensive training in advanced formulation design, supramolecular self-assembly, and ionic-liquid chemistry. Core experimental skills will include rheology, spectroscopy, microscopy, and analytical method development. Training will also cover computational modelling for excipient–drug interaction prediction and data-driven formulation optimisation. In addition, the student will gain experience in translational pharmaceutics, regulatory considerations, scientific writing, and dissemination through conferences, industry collaboration, and interdisciplinary workshops. Expected impact activities The project will generate high-impact research outputs in advanced drug delivery, leading to publications in top-tier journals and conference presentations. Outcomes will contribute to developing scalable drug delivery systems for unmet clinical needs. Engagement activities will include presentations at scientific meetings, collaboration with industry and clinical partners, and outreach through QUB research showcases, enhancing public awareness of innovative, patient-centred therapeutic technologies.